Developing the clinical trial management tool
Prof. Norbert Graf - Saarland University, Germany
Prof. Norbert Graf talks about how the Personalized Medicine project started, who's involved, the development of the clinical trial management tools and who will benefit from it. He also talks about checking the tools reliability and what success looks like for the project.
The ALGA Questionnaire
Prof. Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
Prof. Gordon McVie discusses what personalised medicine and patient empowerment means and how the ALGA questionnaire can help doctors treat their patients more effectively.
The ObTiMA tool
Dr Simona Rossi - Swiss Institute of Bioinformatics, Switzerland
Dr Simona Rossi talks about ObTiMA as a clinical trial management tool, her involvement in the usability of the tool and the difference it will make to doctors and patients.
Developing software for clinical trials
Holger Stenzhorn - Saarland University Hospital, Germany
Holger Stenzhorn discusses his involvement with the Personalized Medicine project to develop software for clinical trials. He explains the benefits to doctors and patients, collecting feedback to ensure that it's successful and what's next for the future.
Dr Gabriele Weiler - Fraunhofer IBMT, Germany
Dr Gabriele Weiler discusses the role of biobanking and its importance within the Personalized Medicine project. She talks about the motivation to develop the tool, its functionality, how it benefits patients and ensuring data protection.
The perspective of an IT-Specialist
Dr Marian Bubak – AGH University of Science and Technology Kraków, Poland
Dr Marian Bubak of University of Science and Technology in Kraków, Department of Computer Science, talks about personalised medicine from his perspective as a computer scientist.
Pitfalls of personalised medicine and how to overcome them
Dipl. Inform. Stephan Kiefer – Fraunhofer Institute for Biomedical Engineering IBMT St. Ingbert, Germany
Dipl. Inform. Stephan Kiefer of Fraunhofer Institute for Biomedical Engineering IBMT in St. Ingbert, Department of Telematics and Intelligent Health Systems, discusses the pitfalls of personalised medicine and offers solutions on how to overcome them.
The benefits for patients
Prof. Dr Dr Thomas Lengauer – Max-Planck-Institute for Informatics Saarbrücken, Germany
Prof. Dr Dr Thomas Lengauer is Director of the Max-Planck-Institute for Informatics at Saarbrücken. He talks about the benefits of personalised medicine for patients.
The role of the patients
Research Prof. Georgios Stamatakos – National Technical University of Athens, Greece
Dr Georgios Stamatakos is Research Professor at the Institute of Communication and Computer Systems where he leads the In-Silico Oncology Group. He discusses the role of patients in personalised medicine.
Integration of complex clinical and biological data
Prof. Kathy Pritchard-Jones – University College London, U.K.
Prof. Kathy Pritchard-Jones is Professor of Paediatric Oncology at the Institute of Child Health at University College London. She is Chief Investigator for several phase I-III trials in childhood and adolescent cancer, Vice Chair of the SIOP Renal Tumours Study Group and Chair of the SIOP Wilms tumour Biology Committee. As a keynote speaker at the summer school, Prof Pritchard-Jones talks about integrating complex clinical and biological data to improve risk stratification and treatment of cancer.
Law and Ethics
Prof. Dr Nikolaus Forgó – Leibniz University Hannover, Germany
Prof. Dr Nikolaus Forgó is full Professor for Legal Informatics and ICT-Law and Co-Director of the Institute for Legal Informatics (IRI) at Leibniz University Hannover. He is a member of the Scientific Advisory Board of the Virtual Physiological Human Network of Excellence and President of the Center for Data Protection (CDP). As a keynote speaker at the Summer School, he delivers a lecture on Law & Ethics.
ALGA-C Patient Profiler
Custodix Anonymisation Tool
Concept Explorer is a tool which helps to visually explore associations between drugs, adverse events, diseases and pathways with the aim of promoting the generation of novel hypotheses.
Achievements in p-medicine for clinicians and patients
Prof. Gordon McVie - European Institute of Oncology, Milan, Italy
Now that the p-medicine project has ended, Prof. Norbert Graf, coordinator of p-medicine, and Prof. Gordon McVie involved in the project via ecancer are summing up some of the most important achievements made in the course of last 4.5 years. Their emphasis is on explaining how these achievements can help clinicians in the future and how the tools developed in p-medicine will help patients to be better informed about their treatment.
ECRIN’s work and collaboration with p-medicine
Prof. Jacques Demontes - Director General of ECRIN
ECRIN (European Clinical Research Infrastructure Network) is a distributed research infrastructure – a distinct organisation that connects research facilities at multiple sites in countries across Europe and provides services for top-level clinical research. This infrastructure creates added value through access to expertise and patients, increasing the reach, diversity, and result quality of clinical trials.
Prof. Jacques Demotes, Director General of ECRIN, gives us an insight into the work of ECRIN and how it will help European institutions to run multinational clinical trials, who it collaborates with, as well as what it hopes to achieve by partnering with the p-medicine project. A part of the interview is dedicated to the special connection ECRIN has with p-medicine.